Drug Profile
Research programme: neuregulins - Acorda Therapeutics
Alternative Names: Neuregulin 2 protein; NRG-2Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Acorda Therapeutics
- Class Nerve tissue proteins; Neuregulins
- Mechanism of Action Epidermal growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Heart failure; Neurological disorders
Most Recent Events
- 01 Apr 2024 Discontinued - Preclinical for Heart failure in USA (SC) as company files for bankruptcy
- 01 Apr 2024 Discontinued - Preclinical for Neurological disorders in USA (SC) as company files for bankruptcy
- 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in USA (SC)